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Association Analysis of Drug Metabolizing Enzyme Gene
Polymorphisms in AIDS Patients with Cutaneous Reactions
to Sulfonamides
To the Editor:
The use of anti-infectious sulfonamides is complicated by
the unusually high rate of cutaneous drug reactions (CDR)
(Eliaszewicz et al, 2002). Theoretically, variation in the bioac-
tivation of sulfonamides and the detoxification of the hydro-
xylamine and nitroso- may determine this susceptibility (van
der Ven et al, 1991). Following this hypothesis, drug-metab-
olizing enzyme gene polymorphisms were evaluated as
markers for CDR to sulfonamides in AIDS. Glutathione
S-transferase M1 and glutathione S-transferase T1 null gen-
otypes, slow N-acetyl-transferase 2 (NAT2) genotypes, a
slow acetylator phenotype, and glutathione deficiency were
not shown to be major predisposing factors (Pirmohamed
et al, 2000; Wolkenstein et al, 2000; O’Neil et al, 2002;
Alfirevic et al, 2003). Glutathione S-transferase P1 (GSTP1)
and cytochrome P450 2C9 (CYP2C9) were also investigated
(Pirmohamed et al, 2000). The GSTP1A/A and CYP2C92/3
genotypes were over-represented in the hypersensitive group
without reaching significance. Given the power of the study, a
minor effect of these enzymes could not be excluded.
We undertook a new genotyping study in our previously
established Epitox cohort of AIDS patients to evaluate
GSTP1, CYP2C9, and NQO1, myeloperoxidase genetic po-
lymorphism as risk factors for CDR to sulfonamides (Lon-
don et al, 1997; Harth et al, 2000; Eliaszewicz et al, 2002).
Twenty-nine females and 107 males were included, 76
with Pneumocystis jirovecii pneumonia and 60 with cerebral
toxoplasmosis. Their mean age was 37  8 y old. At inclu-
sion, the mean CD4þ cell count was 56  78 cells per mm3.
During the follow-up, 48 patients among the 136 (35%) de-
veloped a CDR to sulfonamide (maculo-papular rash
(n¼41), severe pruritus (n¼4), urticaria (n¼1), exfoliative
dermatitis (n¼1), Stevens–Johnson syndrome (n¼1)).
The frequencies of the genotypes of these different en-
zymes in the patients with or without CDR to sulfonamides
and the suspected associations with CDR are shown in
Table I. The genotyping was limited by DNA samples con-
summation but these subgroups of patients were not
different from the whole cohort for their main characteris-
tics (data not shown).
Variables with a pp0.2 including those of our previous
study were included in a multivariate analysis: age o36 y,
previous history of CDR, absence of prophylaxis, CD4þ
cells o27 per mm3, CD8þ cells 4460 per mm3, GSTP1,
and CYP 2C9 polymorphisms. The results of the multivari-
ate analysis are shown in Table II.
The study of Pirmohamed et al (2000) and ours showed a
trend, although not significant (po0.10, two sided), in the
association between sulfonamides hypersensitivity and the
GSTP1A/A and CYP 2C91/2 genotypes, respectively.
The data were pooled together. We identified a significant
association between sulfonamides CDR and GSTP1A/A
compared with GSTP1A/B and B/B (p¼0.003). On the
other hand, CYP 2C91/2 compared with CYP 2C91/1
was no more significantly associated with sulfonamides
CDR (p¼ 0.13).
In our study we confirmed the high frequency of CDR
during the treatment with sulfonamides in AIDS. We ruled out
the role of myeloperoxidase and NQO1 polymorphisms. We
also investigated the role of CYP 2C9 and GSTP1. CYP 2C9
metabolizes sulfonamides to the hydroxylamine (Cribb et al,
1995). The amino acid substitutions Arg144 to Cys (CY-
P2C92) and Ile359 to Leu (CYP2C9
3) affect activity of
CYP2C9 toward drugs. Microsomes prepared from cell lines
expressing the allelic variants CYP2C92 and CYP2C93
display a 3- and 20-fold decrease in intrinsic clearance for
sulfamethoxazole, respectively, when compared with wild
type (Gill et al, 1999). In our cohort, contrary to what would
have been expected, the CYP 2C91/2 patients were found
to be over-represented in the CDR group (7.7, 95% confi-
dence interval (CI) 1.6–38.2; p¼ 0.01). This association be-
tween CYP2C9 genotypes and CDR was not confirmed when
the data of the literature were pooled in (Pirmohamed et al,
2000) (Cochran–Mantel–Haenszel test, p¼0.13), leading to
the conclusion that CYP 2C9 does not play a major role.
The GSTP1A/A patients were over-represented in the
CDR group without reaching statistical significance (p¼0.06,
odds ratio (OR)¼8.1, 95% CI¼ 0.9–70.4). A similar finding
was previously published (Pirmohamed et al, 2000), but the
authors suspected that their results could be because of a
type I statistical error. As the trend was identical in both
studies we pooled the data without performing multitesting
correction. Pooling of the data identified a significant asso-
ciation between sulfonamides reactions and the GSTP1
genotypes (p¼0.003). The lower GSTP1B allele frequency
in the CDR group counters what would be expected ac-
cording to the reactive metabolites hypothesis. Increased
toxicity would have been expected from the altered specific
activity and affinity of the GSTP1B allele for electrophilic
substrates. How could variant GSTP1 alleles be protective
against CDR to sulfonamides? Either the wild-type GSTP1
enzyme has the ability to generate more reactive metabolites
than the GSTP1 variant, or the mutant protein displays higher
affinity for sulfonamides (Hu et al, 1997, 1998; Sundberg
et al, 1998; Koeplinger et al, 1999; Pirmohamed et al, 2000).
The role of reactive metabolites in sulfonamides CDR has
been challenged in a recent review (Svensson, 2003). Most
of the polymorphisms in drug metabolism investigated in
the literature including our study do not act as predisposing
Abbreviations: CDR, cutaneous drug reactions; CI, confidence
interval; CYP2C9, cytochrome P450 2C9; GSTP1, glutathione
S-transferase P1; NQO1, NAD(P)H:quinone oxidoreductase; OR,
odds ratio; PCR, polymerase chain reaction
factors for sulfonamides reactions: NAT2, glutathione
S-transferase T1, glutathione S-transferase M1, myelo-
peroxidase and NQO1. GSTP1 acts paradoxically. Our
pharmacogenetic finding adds to the complexity of CDR.
The respective role of parent compound, reactive interme-
diates, free radicals, or nitroso derivatives, their way to act,
haptens, danger signals (Pirmohamed et al, 2002; Svens-
son, 2003), or something else in the context of different CDR
in HIV-positive and -negative populations need to be clar-
ified. The role of GSTP1 variants requires further in vitro and
in vivo studies.
Between August 1995 and January 1997, 136 AIDS pa-
tients treated with sulfamethoxazole plus trimethoprim (co-
trimoxazole) for P. jirovecii pneumonia or sulfadiazine plus
pyrimethamine for cerebral toxoplasmosis were prospectively
included and followed-up for sulfonamide CDR (Eliaszewicz
et al, 2002). Genomic DNA from peripheral leukocytes was
obtained. All patients gave their written informed consent to
the study, which had been approved by the Ethical commit-
tee (CCPPRB Cre´teil-Henri-Mondor). The study was con-
ducted according to the Declaration of Helsinki Principles.
The determination of the GSTP1, 2C9, myeloperoxidase,
NQO1 genotypes was performed as previously described
(Stubbins et al, 1996; Traver et al, 1997; Nedelcheva et al,
1998; Morin et al, 2001; Chevrier et al, 2003).
Patients with and without a CDR were compared as a
function of their genotype using a non-conditional univariate
logistic regression (Wald test, two-tailed). Variables that differed
between the two groups at a pp0.2 were subjected to a mul-
tivariate non-conditional logistic regression model with a step-
wise ascending procedure. Two-tailed a values of 0.05 were
chosen. Predictors of CDR were presented as OR with 95%
CI. All the computations were done with the BMDP statistical
package (Statistical Software Inc., Los Angeles, California).
Only one study reported enzymatic polymorphism
genotypes investigated in our study in HIV-positive
sulfonamides-hypersensitive patients compared with non-
hypersensitive patients (Pirmohamed et al, 2000). To in-
crease the power of our study, we analyzed the pooled data
using the Cochran–Mantel–Haenszel test.
Table I. GSTP1 and 2C9 variant alleles in hypersensitive and non-hypersensitive AIDS patients (our data and pooled data of the
literature)
Variable
Our study: Epitox cohorta Pirmohamed et al Pooled data
CDRþ (n) (%) CDR (n) (%) CDRþ CDR CDRþ CDR p-value
GSTP1 genotyping 36 (100) 62 (100) 56 (100) 89 (100) 92 (100) 151 (100) 0.003b
GSTP1A/A 19 (53) 21 (34) 38 (68) 43 (48) 57 (62) 64 (42)
GSTP1A/B 16 (44) 32 (52) 13 (23) 35 (39) 29 (32) 67 (44)
GSTP1B/B 1 (3) 9 (14) 5 (9) 11 (12) 6 (6) 20 (13)
CYP 2C9 35 (100) 47 (100) 56 (100) 89 (100) 91 (100) 136 (100) 0.13c
CYP 2C91/1 19 (54) 38 (81) 33 (59) 61 (69) 52 (57) 99 (73)
CYP 2C91/2 11 (31) 5 (11) 10 (18) 19 (21) 21 (23) 24 (18)
CYP 2C91/3 5 (14) 4 (8) 8 (14) 8 (9) 13 (14) 12 (9)
CYP 2C92/3 0 (0) 0 (0) 5 (5) 1 (1) 5 (5) 1 (1)
aCDR tended to be more frequent in the GSTP1A/A patients than in the GSTP1B/B group (p¼ 0.06, OR¼ 8.1, 95% CI¼ 0.9–70.4). CDR were
significantly more frequent in the CYP 2C91/2 patients than in the CYP 2C91/1 group (p¼ 0.01, OR¼ 4.4, 95% CI¼ 1.3–14.5). For other enzymes,
myeloperoxidase, NQ01, there was no difference in the frequencies of genotypes between patients with or without CDR (p40.1) (Wald test, two-tailed).
bPooling of the data showed that there was a significant association between sulfonamides hypersensitivity and the GSTP1A/A versus GSTP1A/B
and B/B (p¼0.003).
cPooling of the data did not confirm a significant association between hypersensitivity and the 2C9 1/2 versus 2C91/1 (p¼ 0.13).
CDR, cutaneous drug reactions; GSTP1, glutathione S-transferase P1; OR, odds ratio; CI, confidence interval.
Table II. Multivariate analysis of predictors of cutaneous
reaction to sulfonamides in AIDS patients
OR (95% CI) p-value
History of drug eruption 2.5 (0.7–9.7) 0.18
No prophylaxis 8.0 (2.0–32.5) 0.003
CD8þ cells 4460 per mm3 3.0 (0.9–10.1) 0.08
GSTP1A/B versus GSTP1B/B 4.3 (0.4–46.3) 0.23
GST P1A/A versus GST P1B/B 10.1 (0.9–108.4) 0.06
CYP 2C91/2 versus CYP 2C91/1 7.7 (1.6–38.2) 0.01
CYP 2C91/3 versus CYP 2C91/1 4.1 (0.7–24.4) 0.12
Hosmer—Lemeshow, p¼ 0.91.
OR, odds ratio; CI, confidence interval.
Pierre Wolkenstein, Marie-Anne Loriot,w Antoine Flahault,z Michel
Cadilhac,z Eric Caumes,y Muriel Eliaszewicz,z Philippe Beaune,w
Jean-Claude Roujeau,and Olivier Chosidow,k for The Epitox Group
Department of Dermatology, Assistance Publique-Hoˆpitaux de Paris,
Hoˆpital Henri-Mondor, and INSERM U659, Universite´ Paris 12, Cre´teil,
France; wINSERM UMRS 490 Molecular Toxicology, Centre Univer-
sitaire des Saints Pe`res, Universite´ Paris 5, and Biochemistry Depart-
ment, Hoˆpital Europe´en Georges-Pompidou, Paris, France;
zEpidemiology, Assistance Publique-Hoˆpitaux de Paris, Hoˆpital Tenon,
Universite´ Paris 6, Paris, France; yDepartment of Infectious Diseases,
Assistance Publique-Hoˆpitaux de Paris, Groupe Hospitalier Pitie´-
Salpeˆtrie`re, Universite´ Paris 6, Paris, France; zDepartment of
Infectious Diseases, Hoˆpital de l’Institut Pasteur, Paris, France; kDepart-
ment of Internal Medicine, Assistance Publique-Hoˆpitaux de Paris, Groupe
Hospitalier Pitie´-Salpeˆtrie`re, Universite´ Paris 6, Paris, France
LETTERS TO THE EDITOR 1081125 : 5 NOVEMBER 2005
We are indebted to Agnes Bazelly for technical assistance. This
work was supported by the following grants: SIDACTION, Fondation
pour la Recherche Me´dicale, De´le´gation a` la Recherche Clinique de
l’AP-HP (EMUL 940703), Agence Franc¸aise de Se´curite´ Sanitaire des
Produits de Sante´, Ligue Nationale contre le Cancer. This work was
presented in part at the Journe´es Dermatologiques de Paris 2003,
December 2–6.
This work took place in Grand Paris Region, France.
Epitox group: S. Aractingi, C. Bachmeyer, M. Bernier, H. Bocquet, I.
Bourgault-Villada, M. Bouvier, D. Challine-Lehman, T. Clerici, A. Co-
mpagnucci, X. Duval, A. Dallot, S. Dellion, A. M. Fillet, S. Fournier, N.
Franck, M. Guez, J. B. Guiard-Schmid, M. Janier, F. Lacassin, S.
Mansouri, F. Marchal, C. Maslo, J. P. Morini, J. M. Pawlotsky, D. Penso,
C. Picard, O. Picard, J. D. Poveda, J.
Wechsler, P. Saiag
DOI: 10.1111/j.0022-202X.2005.23939.x
Manuscript received May 05, 2005; revised July 14, 2005; accepted for
publication July 15, 2005
Address correspondence to: Pierre Wolkenstein, MD, PhD, Depart-
ment of Dermatology, Hoˆpital Henri-Mondor, F-94010 Cre´teil Cedex,
France. Email: pierre.wolkenstein@hmn.aphp.fr
References
Alfirevic A, Stalford AC, Vilar FJ, Wilkins EG, Park BK, Pirmohamed M:
Slow acetylator phenotype and genotype in HIV-positive patients with
sulphamethoxazole hypersensitivity. Br J Clin Pharmacol 55:158–165,
2003
Chevrier I, Stucker I, Houllier AM, Cenee S, Beaune P, Laurent-Puig P, Loriot MA:
Myeloperoxidase: New polymorphisms and relation with lung cancer risk.
Pharmacogenetics 13:729–739, 2003
Cribb AE, Spielberg SP, Griffin GP: N4-hydroxylation of sulfamethoxazole by
cytochrome P450 of the cytochrome P4502C subfamily and reduction of
sulfamethoxazole hydroxylamine in human and rat hepatic microsomes.
Drug Metab Dispos 23:406–414, 1995
Eliaszewicz M, Flahault A, Roujeau JC, et al: Prospective evaluation of risk factors
of cutaneous drug reactions to sulfonamides in patients with AIDS. J Am
Acad Dermatol 47:40–46, 2002
Gill HJ, Tjia JF, Kitteringham NR, Pirmohamed M, Back DJ, Park BK: The effect of
genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylat-
ion. Pharmacogenetics 9:43–53, 1999
Harth V, Donat S, Ko Y, Abel J, Vetter H, Bruning T: NAD(P)H quinone ox-
idoreductase 1 codon 609 polymorphism and its association to colorectal
cancer. Arch Toxicol 73:528–531, 2000
Hu X, Ji X, Srivastava SK, et al: Mechanism of differential catalytic efficiency of
two polymorphic forms of human glutathione S-transferase P1-1 in the
glutathione conjugation of carcinogenic diol epoxide of chrysene. Arch
Biochem Biophys 345:32–38, 1997
Hu X, Xia H, Srivastava SK, Pal A, Awasthi YC, Zimniak P, Singh SV: Catalytic
efficiencies of allelic variants of human glutathione S-transferase P1-1
toward carcinogenic anti-diol epoxides of benzo[c]phenanthrene and
benzo[g]chrysene. Cancer Res 58:5340–5343, 1998
Koeplinger KA, Zhao Z, Peterson T, Leone JW, Schwende FS, Heinrikson RL,
Tomasselli AG: Activated sulfonamides are cleaved by glutathione-S-
transferases. Drug Metab Dispos 27:986–991, 1999
London SJ, Lehman TA, Taylor JA: Myeloperoxidase genetic polymorphism and
lung cancer risk. Cancer Res 57:5001–5003, 1997
Morin S, Loriot MA, Poirier JM, et al: Is diclofenac a valuable CYP2C9 probe in
humans? Eur J Clin Pharmacol 56:793–797, 2001
Nedelcheva KV, Andersen TI, Erikstein B, Geitvik G, Skovlund E, Nesland JM,
Borresen-Dale AL: Single tube multiplex polymerase chain reaction gen-
otype analysis of GSTM1, GSTT1 and GSTP1: Relation of genotypes to
TP53 tumor status and clinicopathological variables in breast cancer
patients. Pharmacogenetics 8:441–447, 1998
O’Neil WM, MacArthur RD, Farrough MJ, et al: Acetylator phenotype and gen-
otype in HIV-infected patients with and without sulfonamide hypersen-
sitivity. J Clin Pharmacol 42:613–619, 2002
Pirmohamed M, Alfirevic A, Vilar J, Stalford A, Wilkins EG, Sim E, Park BK:
Association analysis of drug metabolizing enzyme gene polymorphisms in
HIV-positive patients with co-trimoxazole hypersensitivity. Pharmacoge-
netics 10:705–713, 2000
Pirmohamed M, Naisbitt DJ, Gordon F, Park BK: The danger hypothesis—
potential role in idiosyncratic drug reactions. Toxicology 181–182:55–63,
2002
Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR: Genetic analysis of the
human cytochrome P450 CYP2C9 locus. Pharmacogenetics 6:429–439,
1996
Sundberg K, Seidel A, Mannervik B, Jernstrom B: Detoxication of carcinogenic
fjord-region diol epoxides of polycyclic aromatic hydrocarbons by glutathi-
one transferase P1-1 variants and glutathione. FEBS Lett 438:206–210,
1998
Svensson CK: Do arylhydroxylamine metabolites mediate idiosyncratic
reactions associated with sulfonamides? Chem Res Toxicol 16:1035–
1043, 2003
Traver RD, Siegel D, Beall HD, Phillips RM, Gibson NW, Franklin WA, Ross D:
Characterization of a polymorphism in NAD(P)H: Quinone oxidoreductase
(DT-diaphorase). Br J Cancer 75:69–75, 1997
van der Ven AJ, Koopmans PP, Vree TB, van der Meer JW: Adverse reactions to
co-trimoxazole in HIV infection. Lancet 338:431–433, 1991
Wolkenstein P, Loriot MA, Aractingi S, Cabelguenne A, Beaune P, Chosidow O:
Prospective evaluation of detoxification pathways as markers of cutane-
ous adverse reactions to sulphonamides in AIDS. Pharmacogenetics
10:821–828, 2000
1082 LETTERS TO THE EDITOR THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
